Xentriaincis A Clinical Stagebiotherapeutics Company Based In Chicagoestablished In 2020Thecompany Specializes In Developing Innovativetherapeutics And Biosimilars Through Strategic Partnershipsfocusing On Addressing Unmet Medical Needs In Complex Drug Development Areasxentria Operates As A Biotech Venturestudiocollaborating With Academic Institutionslifesciences Organizationsand Commercial Entities To Guidedrug Development From Early Concepts To Clinical Trials And Commercialization Xentria Offers Comprehensivedrug Development Partnershipsincluding Support For Intellectual Propertyclinical Trial Designand Regulatory Strategythecompany Manages Global Clinical Trials And Is Actively Advancing Its Biosimilar Portfoliowith Multipleclinical Trials Initiated In 2024 And Moreplanned For 2025Oneof Its Key Products Is Xtmab 16An Anti Tnfimonoclonal Antibody Currently In Phase1B 2A Trials For Pulmonary Sarcoidosisxentria Emphasizes Patient Centric Innovation And Aims To Improvetherapeutic Outcomes Through Authentic Partnerships And Adaptiveapproaches
No conferences found for this company.
| Company Name | Xentria Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
